Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 8
World Journal of Pharmacology and Toxicology received 8 citations as per Google Scholar report
Indexed In
- Google Scholar
- ICMJE
Useful Links
Share This Page
Jean-Marc SABATIER
Aix-Marseille University
France
Biography
Dr. Jean-Marc Sabatier is a Director of research at the French CNRS, with PhD and Habilitation A Diriger Des Recherches (HDR) degrees in Biochemistry and Microbiology and Chief Scientific Officer of Tournoux Biotech, France. He headed several academic research teams like CNRS, INSERM and University, as well as a combined academic-industry research laboratory devoted to the engineering of therapeutic peptides (ERT62, Marseilles, France). He was also a Director of Research for several French private companies as well as a Canadian public company. He acts as a Consultant for top pharmaceutical and cosmetic companies. Dr. Jean-Marc Sabatier contributed to several books in toxinology and virology, and more than 160 scientific articles, 180 communications, and 53 patents in both biology and chemistry. He is a member of 35 Editorial Boards and Editor-in-Chief of scientific journals. He won the ‘Citizen of the Year Award’ from the Nouvel Economiste (1994) for his work on antivirals. He is a member of a dozen scientific societies, such as the ‘American Peptide Society’ (charter member), ‘European Peptide Society’, ‘American Society for Microbiology’, ‘Biochemical Society’ and ‘New-York Academy of Sciences’.
Research Interest
Dr. Jean-Marc Sabatier’s interest includes Drug design and synthesis (peptides and related compounds), Optimization of peptide structure/conformation (to improve bioactivity, selectivity, solubility, and/or stability), Peptide and protein engineering, Development of peptide-based drugs, Evaluation of research projects.
